Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.3 million.

  • Seres Therapeutics' Non-cash Items fell 7727.08% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 7727.08%. This contributed to the annual value of $15.3 million for FY2024, which is N/A changed from last year.
  • Seres Therapeutics' Non-cash Items amounted to $2.3 million in Q3 2025, which was down 7727.08% from $499042.0 recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Non-cash Items peaked at $854.1 million during Q2 2022, and registered a low of $135000.0 during Q3 2023.
  • In the last 5 years, Seres Therapeutics' Non-cash Items had a median value of $8.4 million in 2022 and averaged $69.8 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non-cash Items crashed by 9920.06% in 2023, and later soared by 735655.85% in 2024.
  • Over the past 5 years, Seres Therapeutics' Non-cash Items (Quarter) stood at $28.0 million in 2021, then plummeted by 58.55% to $11.6 million in 2022, then tumbled by 98.84% to $135000.0 in 2023, then surged by 11259.26% to $15.3 million in 2024, then plummeted by 85.08% to $2.3 million in 2025.
  • Its Non-cash Items was $2.3 million in Q3 2025, compared to $499042.0 in Q2 2025 and $15.3 million in Q4 2024.